, Volume 15, Issue 5, pp 303–323

Prophylaxis and Treatment of Influenza Virus Infection

  • Ruth Kandel
  • Kevan L. Hartshorn
Review Article


Influenza virus infections remain an important cause of morbidity and mortality. Furthermore, a recurrence of pandemic influenza remains a real possibility. There are now effective ways to both prevent and treat influenza. Prevention of infection is most effectively accomplished by vaccination. Vaccination with the inactivated, intramuscular influenza vaccine has been clearly demonstrated to reduce serious morbidity and mortality associated with influenza infection, especially in groups of patients at high risk (e.g. the elderly). However, the inactivated, intramuscular vaccine does not strongly induce cell-mediated or mucosal immune responses, and protection induced by the vaccine is highly strain specific. Live, attenuated influenza vaccines administered intranasally have been studied in clinical trials and shown to elicit stronger mucosal and cell-mediated immune responses. Live, attenuated vaccines appear to be more effective for inducing protective immunity in children or the elderly than inactivated, intramuscular vaccines. Additionally, novel vaccine methodologies employing conserved com-ponents of influenza virus or viral DNA are being developed. Preclinical studies suggest that these approaches may lead to methods of vaccination that could induce immunity against diverse strains or subtypes of influenza.

Because of the limitations of vaccination, antiviral therapy continues to play an important role in the control of influenza. Two major classes of antivirais have demonstrated ability to prevent or treat influenza in clinical trials: the adaman-tanes and the neuraminidase inhibitors. The adamantanes (amantadine and rimantadine) have been in use for many years. They inhibit viral uncoating by blocking the proton channel activity of the influenza A viral M2 protein. Limitations of the adamantanes include lack of activity against influenza B, toxicity (especially in the elderly), and the rapid development of resistance. The neuraminidase inhibitors were designed to interfere with the conserved sialic acid binding site of the viral neuraminidase and act against both influenza A and B with a high degree of specificity when administered by the oral (oseltamivir) or inhaled (zanamivir) route. The neuraminidase inhibitors have relatively low toxicity, and viral resistance to these inhibitors appears to be uncommon. Additional novel antivirals that target other phases of the life cycle of influenza are in preclinical development. For example, recombinant collectins inhibit replication of influenza by binding to the viral haemagglutinin as well as altering phagocyte responses to the virus. Recombinant techniques have been used for generation of antiviral proteins (e.g. modified collectins) or oligonucleotides.

Greater understanding of the biology of influenza viruses has already resulted in significant advances in the management of this important pathogen. Further advances in vaccination and antiviral therapy of influenza should remain a high priority.


  1. 1.
    Bridges C, Winquist A, Fukuda K, et al. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 49: 1–28PubMedGoogle Scholar
  2. 2.
    Hartshorn K. Etiology of bacterial superinfections complicating influenza viral infection. In: Brown L et al., editors. Options for the control of influenza. Amsterdam: Elsevier Science, 1996: 499–508Google Scholar
  3. 3.
    Watson J, Nicholas S, James P. Meningococcal infections and influenza: do surveillance data support an association. In: Brown L et al., editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 82–4Google Scholar
  4. 4.
    Cartwright KAV, Jones DM, Smith AJ, et al. Influenza A virus and meningococcal disease. Lancet 1991; 338: 554–7PubMedGoogle Scholar
  5. 5.
    Hartshorn KL, Liou LS, White MR, et al. Neutrophil deactivation by influenza A virus: role of hemagglutinin binding to specific sialic acid-bearing cellular proteins. J Immunol 1995; 154: 3952–60PubMedGoogle Scholar
  6. 6.
    Abramson JS, Mills EL. Depression of neutrophil function induced by viruses and its role in secondary microbial infections. Rev Infect Dis 1988; 10: 326–41PubMedGoogle Scholar
  7. 7.
    Abramson JS, Giebink GS, Quie PG. Influenza A virus-induced polymorphonuclear leukocyte dysfunction in the pathogenesis of experimental pneumococcal otitis media. Infect Immunol 1982; 36: 289–96Google Scholar
  8. 8.
    Tashiro M, Ciborowski P, Klenk H, et al. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987; 325: 536–7PubMedGoogle Scholar
  9. 9.
    Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982; 4: 25–44PubMedGoogle Scholar
  10. 10.
    Buchman C, Doyle W, Skoner D, et al. Influenza A virus-induced acute otitis media. J Infect Dis 1995; 172: 1348–51PubMedGoogle Scholar
  11. 11.
    Gorse G, Otto E, Daughaday C, et al. Influenza virus vaccination of patients with chronic lung disease. Chest 1997; 112: 1221–33PubMedGoogle Scholar
  12. 12.
    Gorse G, Campbell M, Otto E, et al. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J Infect Dis 1995; 172: 1–10PubMedGoogle Scholar
  13. 13.
    McElhaney J, Upshaw C, Hooten J, et al. Responses to influenza vaccination in different T-cell subsets: a comparison of healthy young and older adults. Vaccine 1998; 16: 1742–7PubMedGoogle Scholar
  14. 14.
    Bernstein E, Kaye D, Abrutyn E, et al. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999; 17: 82–94PubMedGoogle Scholar
  15. 15.
    Laver W, Bischofberger N, Webster R. Disarming flu viruses. Sci Am 1999; 280: 78–87PubMedGoogle Scholar
  16. 16.
    Kilbourne ED. Influenza. New York: Plenum, 1987Google Scholar
  17. 17.
    Reid A, Fanning T, Janczewski T, et al. Characterization of the 1918 ’spanish’ influenza virus neuraminidase gene. Proc Natl Acad Sci USA 2000; 97: 6875–9Google Scholar
  18. 18.
    O’Neill E, Krauss S, Riberdy J, et al. Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection of C57BL/6 mice. J Gen Virol 2000; 81: 2689–96PubMedGoogle Scholar
  19. 19.
    Lamb R, Krug R. Orthomyxoviridae: the viruses and their replication. In: Fields B et al., editors. Fields virology. Philadelphia: Lippincott-Raven, 1996: 1353Google Scholar
  20. 20.
    Hartshorn KL, Crouch EC, White MR, et al. Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses. J Clin Invest 1994; 94: 311–9PubMedGoogle Scholar
  21. 21.
    Crouch E, Hartshorn K, Ofek I. Collectins and pulmonary innate immunity. Immunol Rev 2000; 173: 52–65PubMedGoogle Scholar
  22. 22.
    Holmskov U, Mollenhauer J, Madsen J, et al. Cloning of gp340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci 1999; 96: 10794–9PubMedGoogle Scholar
  23. 23.
    Edwards M, Dimmock N. Two influenza A virus-specific Fabs neutralize by inhibiting virus attachment to target cells, while neutralization by their IgGs is complex and occurs simultaneously through fusion inhibition and attachment inhibition. Virology 2000; 278: 423–35PubMedGoogle Scholar
  24. 24.
    Belshe R, Gruber W, Mendelman P, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133–7PubMedGoogle Scholar
  25. 25.
    Goto H, Kawasaki Y. A novel mechanism for acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA 1998; 95: 10224–8PubMedGoogle Scholar
  26. 26.
    Steinhauer D. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999; 258: 1–20PubMedGoogle Scholar
  27. 27.
    Sakaguchi T, Tu Q, Pinto L, et al. The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer. Proc Natl Acad Sci 1997; 94: 5000–5PubMedGoogle Scholar
  28. 28.
    Graham M, Braciale T. Resistance to recovery from lethal influenza viral infection in B lymphocyte deficient mice. J Exp Med 1997; 186: 2063–8PubMedGoogle Scholar
  29. 29.
    Fu T, Friedman A, Ulmer J, et al. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997; 71: 2715–21PubMedGoogle Scholar
  30. 30.
    Varghese J, Laver W, Colman P. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983; 303: 35–80PubMedGoogle Scholar
  31. 31.
    Itzstein MV, Wu W, Kok G, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418–33Google Scholar
  32. 32.
    Liu C, Air G. Selection and characterization of a neuraminidase minus mutant of influenza virus and its rescue by cloned neur-aminidase genes. Virology 1993; 194: 403–7PubMedGoogle Scholar
  33. 33.
    Foster D, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296–307PubMedGoogle Scholar
  34. 34.
    Nichol K, Margolis K, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84PubMedGoogle Scholar
  35. 35.
    Nicholson K, Stone A, Botha J, et al. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. In: Brown L et al., editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 113–122Google Scholar
  36. 36.
    Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344: 889–96PubMedGoogle Scholar
  37. 37.
    Kramarz P, DeStefano F, Garguillo PM, et al. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr 2001; 138; 306–10PubMedGoogle Scholar
  38. 38.
    Potter J, Stott D, Roberts M, et al. Influenza vaccination of health care workers in long term care hospitals reduces the mortality of elderly patients. J Infect Dis 1997; 175: 1–6PubMedGoogle Scholar
  39. 39.
    Carman W, Elder A, Wallace L, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled study. Lancet 2000; 355: 93–7PubMedGoogle Scholar
  40. 40.
    Nichol K, Lind A, Margolis K, et al. The effectiveness of vaccination against influenza in healthy working adults. N Engl J Med 1995; 333: 889–93PubMedGoogle Scholar
  41. 41.
    Lasky T, Terracciano G, Magder L, et al. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med 1998; 339: 1797–802PubMedGoogle Scholar
  42. 42.
    Wijdicks E, Fletcher D, Lawn N. Influenza vaccine and the risk of relapse of Guillain-Barré syndrome. Neurology 2000; 55: 452–3PubMedGoogle Scholar
  43. 43.
    Keyser JD, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations of multiple sclerosis. J Neurol Sci 1998; 159: 51–3PubMedGoogle Scholar
  44. 44.
    Glesby M, Hoover D, Farzadegen H, et al. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996; 174: 1332–6PubMedGoogle Scholar
  45. 45.
    Evans K, Kline M. Prolonged influenza A virus infection responsive to rimantadine therapy in a human immunodeficiency virus-infected child. Ped Infect Dis J 1995; 14: 332–4Google Scholar
  46. 46.
    Kiecolt-Glaser J, Glaser R, Gravenstein S, et al. Chronic stress alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci USA 1996; 93: 3043–7PubMedGoogle Scholar
  47. 47.
    Kiecolt-Glaser J, Glaser R. Chronic stress and mortality among older adults. JAMA 1999; 282: 2259–60PubMedGoogle Scholar
  48. 48.
    King J, Treanor J, Fast P, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000; 181: 725–8PubMedGoogle Scholar
  49. 49.
    Treanor J, Mattison H, Dumyati G, et al. Protective effect of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992; 117: 625–33PubMedGoogle Scholar
  50. 50.
    Parkin N, Chiu P, Coelingh K. Genetically engineered temperature-sensitive, attenuated mutants of influenza A virus: clustered charged-to-alanine mutants in PB2. In: Brown L et al., editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 788–94Google Scholar
  51. 51.
    Neumann G, Watanabe T, Ito H, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999; 96: 9345–50PubMedGoogle Scholar
  52. 52.
    Solorzano A, Zheng H, Fodor E, et al. Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice. J Gen Virol 2000; 81: 737–42PubMedGoogle Scholar
  53. 53.
    Arulanandam B, Mittler J, Lee W, et al. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 2000; 164: 3698–704PubMedGoogle Scholar
  54. 54.
    Spellberg B, Edwards JE. Type 1/Type2 immunity in infectious diseases. Clin Infect Dis 2001; 32: 76–102PubMedGoogle Scholar
  55. 55.
    Justewicz D, Pohlman E, Sheehy M, et al. Particle-mediated epidermal delivery of DNA and inactivated virus. In: Brown L et al., editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 763–71Google Scholar
  56. 56.
    Donnelly J, Friedman A, Martinez A, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift. Nature Med 1995; 1: 583–7PubMedGoogle Scholar
  57. 57.
    Shedlock D, Weiner D. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000; 68: 793–806PubMedGoogle Scholar
  58. 58.
    Johnson P, Conway M, Daly J, et al. Plasmid DNA encoding influenza virus haemagglutinin induces Th1 cells and protection against respiratory infection despite its limited ability to generate antibody responses. J Gen Virol 2000; 81: 1737–45PubMedGoogle Scholar
  59. 59.
    Kent S, Zhao A, Best S, et al. Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowl pox virus. J Virol 1998; 72: 10180–8PubMedGoogle Scholar
  60. 60.
    Nguyen H, Ginkel FV, Vu H, et al. Heterosubtypic immunity to influenza A viras infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis 2001; 183: 368–76PubMedGoogle Scholar
  61. 61.
    Neirynck S, Deroo T, Saelens S, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Med 1999; 5: 1157–63PubMedGoogle Scholar
  62. 62.
    Drinka P, Gravenstein S, Schilling M, et al. Duration of antiviral prophylaxis during nursing home outbreaks of influenza A. Arch Intern Med 1998; 158: 2155–9PubMedGoogle Scholar
  63. 63.
    Hayden F. Antivirals for pandemic influenza. J Infect Dis 1997; 176Suppl. 1: S56–61PubMedGoogle Scholar
  64. 64.
    Scholtissek C, Webster R. Long-term stability of the anti-influenza A compounds amantadine and rimantadine. Antiviral Res 1998; 38: 213–5PubMedGoogle Scholar
  65. 65.
    AHFS. Rimantadine hydrochloride. In: AHFS drag information. 1998: 98Google Scholar
  66. 66.
    Sears S, Clements M. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 1987; 31: 1470–3PubMedGoogle Scholar
  67. 67.
    Doyle W, Skinner D, Alper C, et al. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A viras. J Infect Dis 1998; 177: 1260–5PubMedGoogle Scholar
  68. 68.
    Belshe R, Smith M, Hall C, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62: 1508–12PubMedGoogle Scholar
  69. 69.
    Englund J, Champlin R, Wyde P, et al. Common emergence of amantadine and rimantadine resistant influenza A viruses in symptomatic immunocompromised patients. Clin Infect Dis 1998; 26: 1418–24PubMedGoogle Scholar
  70. 70.
    Hayden F, Belshe R, Clover R, et al. Emergence and apparent transmission of rimantadine resistant influenza A virus in families. N Engl J Med 1989; 321: 1696–1702PubMedGoogle Scholar
  71. 71.
    Ziegler T, Hemphill M, Ziegler M, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180: 935–9PubMedGoogle Scholar
  72. 72.
    Keyser L, Karl M, Nafziger A, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used a sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000; 160: 1485–8PubMedGoogle Scholar
  73. 73.
    MIST. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B viras infections. Lancet 1998; 352: 1877–81Google Scholar
  74. 74.
    Hedrick J, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000; 19: 410–7PubMedGoogle Scholar
  75. 75.
    Monto A, Fleming D, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B viras infections. J Infect Dis 1999; 180: 254–61PubMedGoogle Scholar
  76. 76.
    Makela M, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 1999; 40: 42–88Google Scholar
  77. 77.
    Lalezari J, Campion K, Keene O, et al. Zanamivir for treatment of influenza A and B in high-risk patients. Arch Int Med 2001; 161: 212–7Google Scholar
  78. 78.
    Monto A, Robinson D, Herlocher M, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. N Engl J Med 1999; 341: 1336–43Google Scholar
  79. 79.
    Williamson J, Pegram P. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342: 661–2PubMedGoogle Scholar
  80. 80.
    MMWR.Use of neuraminidase inhibitors for treatment of influenza A and B infections. MMWR 1999; 48: 1–9Google Scholar
  81. 81.
    Henney J. From the food and drug administration. JAMA 2000; 284: 1234Google Scholar
  82. 82.
    Treanor J, Hayden F, Vrooman P, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283: 1016–24PubMedGoogle Scholar
  83. 83.
    Nicholson K, Aoki F, Osterhaus A, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Lancet 2000; 355: 1845–50PubMedGoogle Scholar
  84. 84.
    Hayden F, Atmar R, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336–43PubMedGoogle Scholar
  85. 85.
    Welliver R, Monto A, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54PubMedGoogle Scholar
  86. 86.
    McKimm-Breschkin J. Resistance of influenza viruses to neuraminidase inhibitors — Areview. Antiviral Res 2000; 47: 1–17PubMedGoogle Scholar
  87. 87.
    Barnett J, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000; 44: 78–87PubMedGoogle Scholar
  88. 88.
    Gubareva L, Kaiser L, Matrosovich M, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001; 183: 532–7Google Scholar
  89. 89.
    Cram P, Blitz S, Monto A, et al. Diagnostic testing for influenza: review of current status and implications of newer treatment options. Am J Manage Care 1999; 5: 1555–61Google Scholar
  90. 90.
    Sauter NK, Glick GD, Crowther RL, et al. Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin. Biochemistry 1992; 89: 324–8Google Scholar
  91. 91.
    Glick GD, Toogood PL, Wiley DC, et al. Ligand recognition by influenza virus. J Biol Chem 1991; 266: 23660–9PubMedGoogle Scholar
  92. 92.
    Hartshorn K, White M, Voelker D, et al. Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to hemagglutinin to antiviral activity. Biochem J 2000; 351: 449–58PubMedGoogle Scholar
  93. 93.
    Tashiro M, Klenk H, Rott R. Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneumonia, mediated by concomitant bacteria. J Gen Virol 1987; 68: 2039–41PubMedGoogle Scholar
  94. 94.
    Kido H, Beppu Y, Imamura Y, et al. The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses. Bio-polymers (Peptide Science) 1999; 51: 71–86Google Scholar
  95. 95.
    Tu Q, Pinto L, Luo G, et al. Reversible inhibition of the influenza virus M2-ion channel by a spirene containing compound, BL 1743. In: Brown L et al., editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 822–9Google Scholar
  96. 96.
    Hoffman L, White J, Kuntz I. Fusion mechanism of the influenza hemagglutinin: inhibitor design. In: Brown L et al., editors. Options for the control of influenza III. Amsterdam: Elsevier, 1996: 830–6Google Scholar
  97. 97.
    Greengard O, Poltoratskaia N, Leikina E, et al. The anti-influenza viras agent 4-GU-DANA (Zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J Virol 2000; 74: 11108–14PubMedGoogle Scholar
  98. 98.
    Mizuta T, Fujiwara B, Hatta T, et al. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance sur-vival of mice infected with influenza A. Nature Biotech 1999; 17: 583–7Google Scholar
  99. 99.
    Finley J, Atigadda V, Duarte F, et al. Novel aromatic inhibitors of influenza neuraminidase make selective interactions with conserved residues and water molecules in the active site. J Mol Biol 1999; 293: 1107–19PubMedGoogle Scholar
  100. 100.
    Reading P, Morey L, Crouch E, et al. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol 1997; 71: 8204–12PubMedGoogle Scholar
  101. 101.
    Travis S, Singh P, Walsh M. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol 2001; 13: 89–95PubMedGoogle Scholar
  102. 102.
    Daher K, Selsted M, Lehrer R. Direct inactivation of viruses by human granulocyte defensins. J Virol 1986; 60: 1068–74PubMedGoogle Scholar
  103. 103.
    Hill C, Yee J, Selsted M, et al. Crystal structure of defensin HNP-3, and amphiphilic dimer: mechanisms of membrane permeabilization. Science 1991; 251: 1481–5PubMedGoogle Scholar
  104. 104.
    Yang D, Chertov O, Bykovshaia S, et al. β defensins: linking innate and adaptive immunity through dendritic cells and T cell CCR6. Science 1999; 286: 525–8PubMedGoogle Scholar
  105. 105.
    Madsen J, Kliem A, Tornoe I, et al. Localization of lung surfactant protein D on mucosal surfaces in human tissues. J Immunol 2000; 164: 5866–70PubMedGoogle Scholar
  106. 106.
    Turner M. Functional aspects of mannose binding protein. In: Sastry K, Ezekowitz R, editors. Collectins and innate immunity. Austin, Texas: RG Landes, 1996: 73–97Google Scholar
  107. 107.
    Garred P, Madsen H, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997; 349: 236–40PubMedGoogle Scholar
  108. 108.
    Koch A, Melbye M, Sorensen P, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001; 285: 1316–21PubMedGoogle Scholar
  109. 109.
    Hartshorn K, Crouch E, White M, et al. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 1998; 274: L958–69PubMedGoogle Scholar
  110. 110.
    LeVine A, Bruno M, Huelsman K, et al. Surfactant protein A deficient mice are susceptible to group B streptococcal infection. J Immunol 1997; 158: 4336–40PubMedGoogle Scholar
  111. 111.
    LeVine A, Gwozdz J, Stark J, et al. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999; 103: 1015–21PubMedGoogle Scholar
  112. 112.
    Reading P, Allison J, Crouch E, et al. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose. J Virol 1998; 72: 6884–7PubMedGoogle Scholar
  113. 113.
    Postle A, Mander A, Reid K, et al. Deficient hydrophilic surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol 1999; 20: 90–8PubMedGoogle Scholar
  114. 114.
    Hickling T, Malhotra R, Sim R. Human surfactant protein A exists in several different oligomeric states: oligomer size distribution varies between patient groups. Mol Med 1998; 4: 266–75PubMedGoogle Scholar
  115. 115.
    DiAngelo S, Lin Z, Wang G, et al. Novel, nonradioactive, simple and multiplex PCR-cRFLP methods for genotyping human SP-A and SP-D marker alleles. Dis Markers 1999; 15: 269–81PubMedGoogle Scholar
  116. 116.
    Floros J, Lin H, Garcia A, et al. Surfactant protein marker alleles identify a subgroup of tuberculosis patients in a Mexican population. J Infect Dis 2000; 182: 1473–8PubMedGoogle Scholar
  117. 117.
    Anders EM, Hartley CA, Jackson DC. Bovine and mouse serum B inhibitors of influenza Avirus are mannose-binding lectins. Proc Natl Acad Sci (USA) 1990; 87: 4485–9Google Scholar
  118. 118.
    Hartshorn KL, Sastry K, White MR, et al. Human mannose-binding protein functions as an opsonin for influenza A viruses. J Clin Invest 1993; 91: 1414–20PubMedGoogle Scholar
  119. 119.
    Hartshorn KL, Sastry K, Brown D, et al. Conglutinin acts as an opsonin for influenza A viruses. J Immunol 1993; 151: 1–9Google Scholar
  120. 120.
    Hartshorn K, Chang D, Rust K, et al. Interactions of recombinant human pulmonary surfactant protein D and SPD multimers with influenza A. Am J Physiol 1996; 271: L753–62PubMedGoogle Scholar
  121. 121.
    White M, Crouch E, Chang D, et al. Enhanced antiviral and opsonic activity of a human mannose binding lectin and surfactant protein D fusion protein. J Immunol 2000; 165: 2108–15PubMedGoogle Scholar
  122. 122.
    Hartshorn K, Reid K, White M, et al. Neutrophil deactivation by influenza A viruses: mechanisms of protection after viral opsonization with collectins and hemagglutination-inhibiting antibodies. Blood 1996; 87: 3450–61PubMedGoogle Scholar
  123. 123.
    Restrepo C, Dong Q, Savov J, et al. Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol 1999; 21: 576–85PubMedGoogle Scholar
  124. 124.
    Harrod K, Trapnell B, Otake K, et al. SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Am J Physiol 1999; 277: 580–8Google Scholar
  125. 125.
    Hickling T, Bright H, Wing K, et al. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 1999; 29: 3478–84PubMedGoogle Scholar
  126. 126.
    Bianca A, Rozendaal MV, Spriel AV, et al. Role of pulmonary surfactant protein D in innate defense against Candida albicans. J Infect Dis 2000; 182: 917–22Google Scholar
  127. 127.
    Madan T, Eggleton P, Kishore U, et al. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun 1997; 65: 3171–9PubMedGoogle Scholar
  128. 128.
    Korfhagen T, Sheftlyevitch V, Burhans M, et al. Surfactant protein D regulates surfactant phospholipid homeostasis in vivo. J Biol Chem 1998; 273: 28438–43PubMedGoogle Scholar
  129. 129.
    Wright J. Immunomodulatory functions of surfactant. Physiol Rev 1997; 77: 931PubMedGoogle Scholar
  130. 130.
    Borron P, Crouch E, Lewis J, et al. Recombinant rat surfactantassociated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol 1998; 161: 4599–603PubMedGoogle Scholar
  131. 131.
    Hartshorn K, Sastry K, Chang D, et al. Enhanced antiinfluenza activity of a recombinant pulmonary surfactant protein D and serum conglutinin fusion protein. Am J Physiol 2000; 278: L90–98Google Scholar
  132. 132.
    Brown-Augsburger P, Hartshorn K, Chang D, et al. Site directed mutagenesis of Cysl5 and Cys20 of pulmonary surfactant protein D: expression of a trimeric protein with altered antiviral properties. J Biol Chem 1996; 271: 13724–30PubMedGoogle Scholar
  133. 133.
    Hartley CA, Jackson DC, Anders ME. Two distinct serum mannose-binding lectins function as B inhibitors of influenza virus: identification of bovine serum B inhibitor as conglutinin. J Virol 1992; 66: 4358–63PubMedGoogle Scholar
  134. 134.
    Reading P, Allison J, Crouch E, et al. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose? J Virol 1998; 72: 6884–7PubMedGoogle Scholar
  135. 135.
    Benne CA, Kraaijeveld CA, van-Strijp JAG, et al. Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J Infect Dis 1995; 171: 335–41PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Ruth Kandel
    • 1
  • Kevan L. Hartshorn
    • 1
  1. 1.Hebrew Rehabilitation Center for Aged, Harvard University School of Medicine and Section of Hematology/OncologyBoston University School of MedicineBostonUSA
  2. 2.Hebrew Re-habilitation Center for AgedInternal Medicine / GeriatricsBostonUSA

Personalised recommendations